ライフサイエンスコーパス: injection site reaction

1 tinued drug due to an adverse event (grade 2 injection site reaction).

2 nts were mostly mild/moderate (most commonly injection site reactions).

3 ) had >=1 emicizumab-related AE (all grade 1 injection-site reactions).

4 ubcutaneous group (mainly grade 1 or 2 local injection-site reactions).

5 e ixekizumab groups were nasopharyngitis and injection site reaction.

6 1 to 2 toxicities including rash, fever, and injection site reaction.

7 articipant discontinued study drug due to an injection site reaction.

8 participant discontinued study drug owing to injection site reaction.

9 The most common adverse event was injection site reaction.

10 thma, upper respiratory tract infection, and injection site reaction.

11 tivitis allergic, headache, oral herpes, and injection-site reaction.

12 s promising but invasive and associated with injection site reactions.

13 erixafor were gastrointestinal disorders and injection site reactions.

14 ociated adverse events were GI disorders and injection site reactions.

15 re mild or moderate, and 94% of patients had injection site reactions.

16 lerated; the most common adverse events were injection site reactions.

17 common adverse events were mild to moderate injection site reactions.

18 were rashes, possible vaccine failures, and injection site reactions.

19 han expected frequency and severity of local injection site reactions.

20 of 23 (96%) participants, most commonly mild injection site reactions.

21 file, consisting mostly of mild self-limited injection site reactions.

22 frequently in active than placebo were mild injection site reactions.

23 The only treatment-related AESIs were injection site reactions.

24 between lerodalcibep and placebo, except for injection site reactions.

25 We described systemic and injection site reactions.

26 the highest incidence were mild to moderate injection site reactions.

27 nemia, fatigue, thrombocytopenia, fever, and injection site reactions.

28 ommon treatment-emergent adverse events were injection site reactions.

29 related adverse events with the exception of injection site reactions.

30 Five patients reported transient injection site reactions.

31 st common grade 3 toxicities were related to injection-site reactions.

32 up discontinued the trial regimen because of injection-site reactions.

33 .2%) discontinued the trial regimen owing to injection-site reactions.

34 107 patients enrolled, 5 had mild, transient injection-site reactions.

35 y treatment-related adverse events were mild injection-site reactions.

36 The most common adverse events were injection-site reactions.

37 The most common adverse events were mild injection-site reactions.

38 ons with IONIS-APO(a)Rx were associated with injection-site reactions.

39 IONIS-APO(a)-LRx was associated with no injection-site reactions.

40 A85A was associated with expected mild local injection-site reactions.

41 ents (AEs) experienced by subjects were mild injection-site reactions.

42 ts were headache (in 12 participants [17%]), injection-site reaction (12 [17%]), and arthralgia (11 [

43 among patients who received bococizumab was injection-site reaction (12.7 per 100 person-years).

44 ed with anakinra frequently developed severe injection-site reactions (12 of 16 [75%]), including ulc

45 iratory tract infections (33-41% vs 35%) and injection-site reactions (13-26% vs 13%).

46 events in drisapersen-treated patients were injection-site reactions (14 patients given continuous d

47 Toxicity was mild, with injection site reactions (20%) and minor infections (10%

48 e health events after both VAR and MMRV were injection site reactions (31% and 27%), rash (28% and 20

49 syndrome (CRS; 40 [59%], all grade 1-2), and injection site reactions (32 [47%]; 31 grade 1).

50 ions, namely regional lymphadenitis (33.9%), injection site reactions (35.2%), osteitis/osteomyelitis

51 s, including regional lymphadenitis (33.9%), injection site reactions (35.2%), osteitis/osteomyelitis

52 t common adverse events in the GA group were injection site reactions (35.5% with GA vs 5.0% with pla

53 eadache (7 [4.8%]), hypertension (4 [2.8%]), injection site reactions (4 [2.8%]), and herpes infectio

54 cipients who were QFT positive reported more injection-site reactions (46 [96%] of 48; 95% CI 85.7-99

55 with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4%

56 b vs 13 [6%] patients receiving placebo) and injection site reactions (60 [16%] vs eight [4%]) occurr

57 d placebo groups, with the most common being injection site reactions (62% to 72%) and fatigue (21% t

58 Patients in the anakinra group had more injection site reactions (68% [17 of 25] vs. 4% [1 of 25

59 lacebo group vs 47% in the dupilumab group), injection site reactions (7% vs 40%, respectively), and

60 Common adverse events included injection site reactions (78% with mipomersen, 31% with

61 ntly more often in the etanercept group were injection-site reactions, accidental injuries, and upper

62 Excluding injection site reactions, adverse events and serious adv

63 Injection site reactions after Tdap immunization were re

64 tidergic drugs associated with allergic-type injection-site reactions also activate Mrgprb2 and MRGPR

65 Local injection-site reactions among the women were more commo

66 Injection site reactions and >3x elevations of alanine a

67 .4%] and 378 [9.5%; 95% CI, 8.6%-10.5%] with injection site reactions and 66 [1.7%; 95% CI, 1.3%-2.1%

68 se events were negligible and included minor injection site reactions and bone pain.

69 Injection site reactions and gastrointestinal symptoms w

70 pI was found to be essential for minimizing injection site reactions and improving subcutaneous bioa

71 Common side effects include injection site reactions and increases in liver enzymes

72 Adverse events included injection site reactions and influenza-like symptoms.

73 ving biologic agents, most frequently citing injection site reactions and lack of efficacy as reasons

74 Injection site reactions and liver enzyme elevations wer

75 of zilebesiran-treated patients (principally injection site reactions and mild hyperkalemia) and 8.0%

76 Injection site reactions and transient elevations of liv

77 Mild-to-moderate injection-site reactions and bone pain were more common

78 Injection-site reactions and conjunctivitis were more co

79 most frequently reported adverse events were injection-site reactions and dizziness, which were self-

80 Common adverse effects were injection-site reactions and fatigue.

81 rticipants in the albiglutide group had more injection-site reactions and fewer gastrointestinal even

82 The most common adverse events were mild injection-site reactions and mild upper respiratory trac

83 These results are consistent with local injection-site reactions and other known, generally mild

84 g both adults and children, the incidence of injection-site reactions and symptoms (e.g., feverishnes

85 t common adverse events with rilonacept were injection-site reactions and upper respiratory tract inf

86 experienced a garadacimab-related TEAE (mild injection-site reaction), and patient 3 (HAE-FXII) exper

87 y vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermal

88 were assessed by monitoring adverse events, injection site reactions, and laboratory test results.

89 he required large drug dosing volumes, local injection-site reactions, and frequency of injections.

90 pt alone, 3.7-7.4% for combination therapy), injection-site reactions, and neutropenia was increased

91 events associated with etanercept were mild injection-site reactions, and no patient withdrew from t

92 t blocks, macular edema, infusion reactions, injection-site reactions, and secondary autoimmune adver

93 hvCNTF, in a dose-related fashion, with mild injection site reactions as the most frequently reported

94 ommon adverse events including headache, new injection site reaction, asthenia, abdominal pain, Crohn

95 ally well tolerated and associated with more injection-site reactions, but less mucositis than placeb

96 Injection site reactions, chills, and pyrexia were the m

97 Aside from injection-site reactions, common treatment-emergent adve

98 inees experienced mild-to-moderate solicited injection site reactions, compared with 47% of placebo r

99 ts, as follows, appeared to be dose related: injection site reactions, cough, asthenia, nausea, anore

100 Median injection site reaction duration was 3 days (IQR 2 to 4)

101 both groups, and mild-to-moderate transient injection-site reactions (eg, erythema, pruritus) were t

102 Injection site reactions, fever, headache, malaise, and

103 rall frequency in the PIXY321 group included injection-site reactions, fever, chills, abdominal pain,

104 Most AEs were mild local injection site reactions following intradermal vaccinati

105 There was a trend to more injection-site reactions for HD-TIV after the second vac

106 Injection site reactions (four or more hours post dose)

107 6 patients referred with localized cutaneous injection-site reactions from January 20 through Februar

108 reported symptoms and signs included fever, injection site reactions, fussiness, rashes, and urticar

109 including employees who reported onset of an injection site reaction >=48 hours after administration

110 The most common reported side effect is injection site reactions (>50% of patients).

111 s were for nonspecific adverse events (e.g., injection-site reactions, headache) on days 1-2 after va

112 uently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followe

113 unded product and has been reported to cause injection site reactions in multiple species, including

114 n the occurrence of significantly more local injection site reactions in patients treated with SC ada

115 ich was mainly because of a higher number of injection site reactions in the anakinra group.

116 We noted grade 1-2 injection-site reactions in 36 (33%) of 110 patients in

117 similar in the three groups, except for more injection-site reactions in recipients in the double-dos

118 dverse events related to vaccine were mainly injection-site reactions in the M72/AS01(E-4) group (8%

119 t differ between the groups, aside from more injection-site reactions in the omalizumab group.

120 ted groups during the open-label period were injection site reactions (in 20 [26%] of 77 patients), h

121 nes than with placebo; these events included injection-site reactions (in 28.5% of the patients in th

122 s associated with peginterferon beta-1a were injection site reactions, influenza-like symptoms, pyrex

123 Detailed clinical (including injection site reaction (ISR) grading), plasma pharmacok

124 injection, 43 (30%) experienced at least one injection site reaction (ISR).

125 ous administration and the high incidence of injection site reactions (ISRs) in 98 % of patients.

126 Overall, 4%-7% of injection site reactions (ISRs) were grade 3.

127 Injection site reactions (ISRs) were the most common adv

128 %) of 87 patients in the MesoPher group, and injection-site reactions (itch, erythema, and induration

129 varied in efficacy, administration regimen, injection-site reaction, joint pain, out-of-pocket cost,

130 igh incidence of transient, mild-to-moderate injection-site reactions, long-acting cabotegravir was w

131 o received long-acting therapy, 86% reported injection-site reactions (median duration, 3 days; mild

132 SC injection site reactions (mostly mild) occurred in 19 SC

133 t common grade 2 or higher adverse event was injection site reaction (n = 7, 78%).

134 lecystitis (n=2), phototoxic skin (n=5), and injection site reactions (n=7).

135 Injection-site reactions, nasopharyngitis, nausea, and h

136 frequent treatment-related adverse event was injection-site reaction (nine [22%] of 41 patients).

137 articipants having adverse events (excluding injection site reactions); no treatment-related deaths o

138 common treatment-related adverse events were injection-site reactions, observed in 15 of 36 (41.6%) p

139 ents should be aware that self-limited local injection site reactions occur more frequently following

140 Injection site reactions occurred in 20 of 106 patients

141 Injection site reactions occurred in 3.8% of patients re

142 Few injection-site reactions occurred (3%).

143 Injection-site reactions occurred in 5% of the patients

144 Injection-site reactions occurred in more patients given

145 Injection-site reactions occurred in most patients, but

146 Dose-dependent, generally mild injection-site reactions occurred in up to 12% (8 of 69)

147 Mild injection-site reactions occurred more frequently among

148 14 treatment-related adverse events, mostly injection site reactions, occurred in five children.

149 Adverse events were mostly injection site reactions occurring after QbG10 administr

150 d their first vaccinations to report a local injection site reaction of at least 10.2 cm (4 in) in di

151 perienced 117 adverse drug reactions, mainly injection site reactions of mild intensity following sub

152 Injection-site reactions of grade 1 or 2 in severity wer

153 the participants in the 2 studies developed injection site reactions or paresthesiae.

154 persensitivity reactions, grade 3 or greater injection-site reactions, or fatalities.

155 eater median number of docetaxel cycles) and injection-site reactions (P<.001).

156 e events observed being transient, grade 1/2 injection site reactions (pain, 50%; erythema, 27.5%; pr

157 n in the placebo group, and most were due to injection-site reactions (pain, redness, swelling, and u

158 common olpasiran-related adverse events were injection-site reactions, primarily pain.

159 's short half-life, low bioavailability, and injection site reactions proved to be limitations for an

160 most common adverse events were symptoms of injection-site reactions, reported in 17 (85%) of 20 par

161 The most common adverse events were injection-site reactions, reported in 70 participants (9

162 require injections that sometimes result in injection site reactions, representing a burden and harm

163 Most injection site reactions resolved within 1 hour (70.2%)

164 Injection site reactions (RR, 8.82; 95% CI, 5.04-15.44)

165 mmunomodulatory mechanisms of GA and adverse injection site reactions seen in patients.

166 Local injection site reactions, select systemic symptoms, and

167 reduction in lung cancer risk over 3 years, injection site reaction severity, nonfatal serious infec

168 requently reported adverse events were local injection site reactions such as injection site swelling

169 cholesterol ratio, and there were no serious injection-site reactions, sustained grade 3 or 4 neutrop

170 associated with a higher frequency of local injection site reactions than was the use of needle and

171 a group, vaccine recipients experienced more injection-site reactions than did placebo recipients; ho

172 (11 patients) developed a similar localized injection-site reaction to the second vaccine dose; most

173 Injection-site reactions to the drug were common.

174 ase series study indicate that the localized injection-site reactions to the Moderna COVID-19 vaccine

175 o describe the course of localized cutaneous injection-site reactions to the Moderna COVID-19 vaccine

176 Except for mild injection site reactions, treatment-emergent adverse eve

177 ith the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse eve

178 subcutaneous lenacapavir because of grade 1 injection-site reactions (two for induration and one for

179 Headache, pruritus, fatigue, eosinophilia, injection-site reactions, upper abdominal pain, arthralg

180 Injection site reaction was the most commonly reported T

181 Injection site reaction was the most frequently noted ad

182 In the nedosiran arm, the incidence of injection-site reactions was 9% (all mild and self-limit

183 Minor injection site reactions were common and similar in freq

184 HZ vaccine was well tolerated; injection site reactions were generally mild.

185 Most injection site reactions were grade 1 or 2 (7453 [99%] o

186 Rates of injection site reactions were low.

187 Local injection site reactions were mild and similar across gr

188 Injection site reactions were mild or moderate.

189 Systemic and injection site reactions were mild, transient, and simil

190 Mild injection site reactions were more common in the Cervari

191 Injection site reactions were more frequent in the intra

192 Injection site reactions were more frequent with rilonac

193 Injection site reactions were mostly classified as mild-

194 Injection site reactions were recorded in nine (9%) pati

195 Injection site reactions were reported by 316 (70%) of 4

196 Late-onset injection site reactions were seen in all ACV groups.

197 Injection site reactions were the most common adverse ev

198 Injection site reactions were the most common adverse ev

199 Injection site reactions were the most common adverse ev

200 Mild injection site reactions were the most common adverse ev

201 Injection site reactions were the most common individual

202 a multi-agent pre-medication regimen; local injection site reactions were the most commonly seen adv

203 Injection site reactions were the most frequently report

204 Thrombocytopenia and injection-site reactions were common adverse events.

205 Injection-site reactions were common.

206 The most common lenacapavir-related injection-site reactions were erythema (27%, 28 of 105),

207 citinib, whereas rates of conjunctivitis and injection-site reactions were higher for patients who re

208 se events, and rates of hypersensitivity and injection-site reactions were low.

209 Injection-site reactions were mild (3648 [84%] of 4360 i

210 Injection-site reactions were more common in the bocociz

211 Injection-site reactions were more common in the lenacap

212 Vaccine-related injection-site reactions were more common in the vaccine

213 Safety was similar between treatment arms; injection-site reactions were more common with dupilumab

214 dose of zilebesiran of 200 mg or more; mild injection-site reactions were observed.

215 Mild, transient injection-site reactions were reported in 38% of lumasir

216 Injection-site reactions were reported in 81.4% of the p

217 Injection-site reactions were the most commonly reported

218 of mild adverse reactions (lymphadenitis and injection site reactions) were reported in vaccinees old

219 verity of reported adverse events, including injection site reactions, were similar in the generic dr

220 Adverse events, including injection-site reactions, were reported.

221 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients w

222 T-1249 was generally well tolerated; injection site reactions, which were generally mild, wer

223 frequencies in all 4 treatment groups except injection site reactions, which were more common in adal

224 were similar across both groups, apart from injection site reactions, which were more frequent in th

225 ents were similar between groups, except for injection-site reactions, which were higher in the 300-m

226 eurocognitive events), with the exception of injection-site reactions, which were more common with ev

227 The most frequent adverse event was injection-site reactions, which were reported in 62% of

228 most frequent adverse events were mild local injection-site reactions, which were reported in all (15

229 treatment of opioid use disorder, except for injection-site reactions, which were reported in more th

230 The most common adverse event was injection-site reaction with one patient in the group of

231 versus control, except for a higher rate of injection-site reactions with alirocumab.

232 Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse event

233 ommon treatment-related adverse effects were injection site reactions, with mild pain occurring in 2.

234 the occurrence of solicited and unsolicited injection-site reactions within 84 days after vaccinatio